|
業務類別
|
Biotechnology |
|
業務概覽
|
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel(resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. |
| 公司地址
| 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104 |
| 電話號碼
| +1 267 759-3100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cabalettabio.com |
| 員工數量
| 156 |
| Dr. Steven Nichtberger,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 659.55K |
28/04/2026 |
| Dr. Gwendolyn K. Binder, PhD |
President, Science and Technology |
美元 516.70K |
28/04/2026 |
| Mr. Steve Gavel |
Chief Commercial Officer |
-- |
28/04/2026 |
| Mr. Anup Marda, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
28/04/2026 |
| Mr. David J. Chang, M.D.,M.P.H. |
Chief Medical Officer |
美元 516.70K |
28/04/2026 |
| Mr. Michael Gerard, J.D. |
General Counsel and Secretary |
-- |
28/04/2026 |
| Mr. Arun Das, M.D. |
Chief Business Officer |
-- |
28/04/2026 |
|
|
| Mr. Richard C. Henriques, M.B.A. |
Independent Director |
28/04/2026 |
| Dr. Steven Nichtberger,M.D. |
Chairman of the Board, President and Chief Executive Officer |
28/04/2026 |
| Ms. Shawn Cline Tomasello, M.B.A. |
Independent Director |
28/04/2026 |
| Dr. Catherine Bollard, M.D.,MB.Ch.B. |
Independent Director |
28/04/2026 |
| Mr. Mark Simon, M.B.A. |
Independent Director |
28/04/2026 |
| Dr. Scott C. Brun, M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
